Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 15 | 2022 | 358 | 1.370 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 15 | 2022 | 471 | 0.790 |
Why?
|
| Lymphoma, Non-Hodgkin | 5 | 2010 | 53 | 0.650 |
Why?
|
| Hodgkin Disease | 6 | 2010 | 54 | 0.650 |
Why?
|
| Stem Cell Transplantation | 8 | 2022 | 80 | 0.570 |
Why?
|
| Transplantation, Autologous | 18 | 2022 | 129 | 0.480 |
Why?
|
| Multiple Myeloma | 7 | 2022 | 366 | 0.400 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 4 | 2008 | 70 | 0.370 |
Why?
|
| Lymphoma, B-Cell | 3 | 2005 | 61 | 0.310 |
Why?
|
| Transplantation Conditioning | 6 | 2010 | 101 | 0.260 |
Why?
|
| Fever | 2 | 2010 | 68 | 0.250 |
Why?
|
| Radiotherapy | 4 | 2010 | 65 | 0.250 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2006 | 4 | 0.250 |
Why?
|
| Interleukin-12 | 1 | 2006 | 128 | 0.230 |
Why?
|
| Prognosis | 11 | 2010 | 1792 | 0.220 |
Why?
|
| Interleukin-6 | 1 | 2006 | 325 | 0.210 |
Why?
|
| Melphalan | 4 | 2008 | 23 | 0.200 |
Why?
|
| Antibodies, Monoclonal | 2 | 2008 | 878 | 0.200 |
Why?
|
| Neoplasms, Second Primary | 2 | 2016 | 50 | 0.190 |
Why?
|
| Disease-Free Survival | 8 | 2010 | 251 | 0.180 |
Why?
|
| Aged | 21 | 2016 | 14946 | 0.180 |
Why?
|
| Middle Aged | 24 | 2012 | 18266 | 0.170 |
Why?
|
| Adult | 23 | 2012 | 17418 | 0.170 |
Why?
|
| Ifosfamide | 6 | 2010 | 8 | 0.160 |
Why?
|
| Etoposide | 6 | 2010 | 33 | 0.160 |
Why?
|
| Carboplatin | 6 | 2010 | 47 | 0.160 |
Why?
|
| Salvage Therapy | 5 | 2010 | 75 | 0.160 |
Why?
|
| Neutropenia | 4 | 2010 | 68 | 0.150 |
Why?
|
| Treatment Outcome | 13 | 2012 | 5819 | 0.150 |
Why?
|
| Recurrence | 7 | 2012 | 660 | 0.140 |
Why?
|
| Adolescent | 11 | 2010 | 6383 | 0.140 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2010 | 41 | 0.130 |
Why?
|
| Radium | 1 | 2016 | 1 | 0.130 |
Why?
|
| Disease Progression | 4 | 2009 | 1216 | 0.120 |
Why?
|
| Hematologic Neoplasms | 3 | 2012 | 46 | 0.120 |
Why?
|
| Combined Modality Therapy | 8 | 2010 | 375 | 0.120 |
Why?
|
| Survival Rate | 5 | 2008 | 862 | 0.120 |
Why?
|
| Dexamethasone | 3 | 2022 | 211 | 0.120 |
Why?
|
| Humans | 29 | 2022 | 65528 | 0.110 |
Why?
|
| Leukapheresis | 2 | 2012 | 11 | 0.110 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 193 | 0.110 |
Why?
|
| Antineoplastic Agents | 3 | 2008 | 682 | 0.100 |
Why?
|
| Blood Donors | 1 | 2012 | 22 | 0.090 |
Why?
|
| Survival Analysis | 4 | 2009 | 591 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2010 | 60 | 0.090 |
Why?
|
| Myeloablative Agonists | 2 | 2008 | 12 | 0.090 |
Why?
|
| Fibroblast Growth Factor 7 | 2 | 2008 | 3 | 0.090 |
Why?
|
| Male | 19 | 2016 | 31073 | 0.090 |
Why?
|
| Remission Induction | 3 | 2008 | 150 | 0.080 |
Why?
|
| Killer Cells, Natural | 1 | 2012 | 220 | 0.080 |
Why?
|
| Thalidomide | 2 | 2007 | 34 | 0.080 |
Why?
|
| Epidemiologic Methods | 2 | 2010 | 67 | 0.080 |
Why?
|
| Hematologic Agents | 1 | 2010 | 3 | 0.080 |
Why?
|
| Lymphocyte Depletion | 1 | 2010 | 102 | 0.080 |
Why?
|
| Female | 18 | 2012 | 34125 | 0.080 |
Why?
|
| Follow-Up Studies | 7 | 2010 | 2511 | 0.070 |
Why?
|
| Razoxane | 1 | 2008 | 2 | 0.070 |
Why?
|
| Mesna | 1 | 2008 | 3 | 0.070 |
Why?
|
| Radiation-Protective Agents | 1 | 2008 | 9 | 0.070 |
Why?
|
| Amifostine | 1 | 2008 | 14 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 2 | 2006 | 15 | 0.070 |
Why?
|
| Oligodendroglioma | 1 | 2008 | 7 | 0.070 |
Why?
|
| Astrocytoma | 1 | 2008 | 12 | 0.070 |
Why?
|
| Bortezomib | 2 | 2022 | 57 | 0.070 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2007 | 16 | 0.070 |
Why?
|
| Amyloidosis | 1 | 2007 | 66 | 0.060 |
Why?
|
| Immunoglobulin G | 1 | 2008 | 469 | 0.060 |
Why?
|
| Carmustine | 1 | 2006 | 11 | 0.060 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2006 | 8 | 0.060 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2006 | 34 | 0.060 |
Why?
|
| Young Adult | 6 | 2012 | 4836 | 0.060 |
Why?
|
| Area Under Curve | 1 | 2006 | 150 | 0.060 |
Why?
|
| Germinal Center | 1 | 2005 | 41 | 0.060 |
Why?
|
| ROC Curve | 1 | 2006 | 293 | 0.060 |
Why?
|
| Stomatitis | 1 | 2004 | 8 | 0.060 |
Why?
|
| Brain Neoplasms | 1 | 2008 | 315 | 0.060 |
Why?
|
| Fibroblast Growth Factors | 1 | 2004 | 76 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2008 | 738 | 0.050 |
Why?
|
| Antigens, CD34 | 1 | 2004 | 53 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2004 | 58 | 0.050 |
Why?
|
| Plasmacytoma | 1 | 2003 | 11 | 0.050 |
Why?
|
| Rituximab | 1 | 2004 | 88 | 0.050 |
Why?
|
| Neoplasm Staging | 3 | 2012 | 547 | 0.050 |
Why?
|
| Antigens, Neoplasm | 1 | 2003 | 136 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2006 | 1286 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2005 | 525 | 0.040 |
Why?
|
| Predictive Value of Tests | 3 | 2010 | 1114 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2010 | 6882 | 0.040 |
Why?
|
| Positron-Emission Tomography | 2 | 2010 | 227 | 0.040 |
Why?
|
| Neoplasms | 1 | 2008 | 1415 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2003 | 928 | 0.030 |
Why?
|
| Aged, 80 and over | 4 | 2012 | 5611 | 0.030 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2016 | 46 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2007 | 301 | 0.030 |
Why?
|
| Incidence | 2 | 2010 | 1410 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 2016 | 129 | 0.030 |
Why?
|
| Lung Diseases | 2 | 2008 | 183 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2022 | 3355 | 0.030 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2012 | 2 | 0.020 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 2012 | 2 | 0.020 |
Why?
|
| Boronic Acids | 1 | 2012 | 28 | 0.020 |
Why?
|
| Pyrazines | 1 | 2012 | 37 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2010 | 1671 | 0.020 |
Why?
|
| Haplotypes | 1 | 2012 | 134 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2012 | 178 | 0.020 |
Why?
|
| Immune Tolerance | 1 | 2012 | 181 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2010 | 2635 | 0.020 |
Why?
|
| Leukopoiesis | 1 | 2010 | 2 | 0.020 |
Why?
|
| Family | 1 | 2012 | 247 | 0.020 |
Why?
|
| Filgrastim | 1 | 2010 | 8 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2012 | 582 | 0.020 |
Why?
|
| Transplantation Chimera | 1 | 2010 | 41 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2010 | 249 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 427 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2010 | 115 | 0.020 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2008 | 9 | 0.020 |
Why?
|
| Lomustine | 1 | 2008 | 2 | 0.020 |
Why?
|
| Procarbazine | 1 | 2008 | 3 | 0.020 |
Why?
|
| Thiotepa | 1 | 2008 | 5 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2010 | 174 | 0.020 |
Why?
|
| Karnofsky Performance Status | 1 | 2008 | 12 | 0.020 |
Why?
|
| Vincristine | 1 | 2008 | 28 | 0.020 |
Why?
|
| Busulfan | 1 | 2008 | 18 | 0.020 |
Why?
|
| Ileus | 1 | 2008 | 6 | 0.020 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2008 | 47 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 370 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2008 | 87 | 0.020 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2007 | 7 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 712 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2010 | 229 | 0.020 |
Why?
|
| Radiation Injuries | 1 | 2008 | 67 | 0.020 |
Why?
|
| Child | 2 | 2010 | 4678 | 0.020 |
Why?
|
| Risk Factors | 2 | 2010 | 5442 | 0.020 |
Why?
|
| Adjuvants, Immunologic | 1 | 2007 | 236 | 0.020 |
Why?
|
| Length of Stay | 1 | 2010 | 831 | 0.010 |
Why?
|
| Kidney | 1 | 2008 | 456 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2008 | 937 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 742 | 0.010 |
Why?
|
| Tissue Array Analysis | 1 | 2005 | 39 | 0.010 |
Why?
|
| Kidney Transplantation | 1 | 2008 | 330 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2006 | 105 | 0.010 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2005 | 18 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 2004 | 25 | 0.010 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2004 | 28 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2010 | 2077 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 882 | 0.010 |
Why?
|
| Melanoma-Specific Antigens | 1 | 2003 | 5 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 822 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 2008 | 413 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2004 | 749 | 0.010 |
Why?
|
| Age Distribution | 1 | 2003 | 259 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2004 | 218 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2003 | 164 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2003 | 289 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 906 | 0.010 |
Why?
|
| Age Factors | 1 | 2005 | 1593 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 2003 | 333 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2007 | 2101 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2003 | 466 | 0.010 |
Why?
|